Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company dedicated to improving the lives of patients and families suffering from seizures, depression and other neuropsychiatric disorders.  Our lead clinical stage drug candidate, ganaxolone, brings a new GABAA receptor modulating mechanism and an extensive safety database with exhibited anxiolytic, anti-seizure and anesthetic activity.Marinus is developing three different convenient dose forms of ganaxolone (IV, capsule, and liquid) to maximize the therapeutic reach to adult and pediatric patients in both acute and chronic care settings where there is a mechanistic rationale for ganaxolone to provide a benefit.

Bank Name Marinus Pharmaceuticals, Inc.
Stock Exchange NASDAQ
Symbol MRNS
Sector Healthcare
Industry Major Pharmaceuticals
Country United States
World Region Amarica
Chairman Mr. Christopher Michael Cashman
CEO Mr. Christopher Michael Cashman
Employees 18
Registered Year 2003